Literature DB >> 17009390

Complementary analysis of microsatellite tumor profile and mismatch repair defects in colorectal carcinomas.

Alfredo Blanes1, Salvador J Diaz-Cano.   

Abstract

Microsatellite instability (MSI) is a prognostic factor and a marker of deficient mismatch repair (MMR) in colorectal adenocarcinomas (CRC). However, a proper application of this marker requires understanding the following: (1) The MSI concept: The PCR approach must amplify the correct locus and accurately identify the microsatellite pattern in the patient's normal tissue. MSI is demonstrated when the length of DNA sequences in a tumor differs from that of nontumor tissue. Any anomalous expansion or reduction of tandem repeats results in extra-bands normally located in the expected size range (100 bp, above or below the expected product), differ from the germline pattern by some multiple of the repeating unit, and must show appropriate stutter. (2) MSI mechanisms: MMR gene inactivation (by either mutation or protein down-regulation as frequently present in deep CRC compartments) leads to mutation accumulation in a cell with every cellular division, resulting in malignant transformation. These mechanisms can express tumor progression and result in a decreased prevalence of aneuploid cells and loss of the physiologic cell kinetic correlations in the deep CRC compartments. MSI molecular mechanisms are not necessarily independent from chromosomal instability and may coexist in a given CRC. (3) Because of intratumoural heterogeneity, at least two samples from each CRC should be screened, preferably from the superficial (tumor cells above the muscularis propria) and deep (tumor cells infiltrating the muscularis propria) CRC compartments to cover the topographic tumor heterogeneity. (4) Pathologists play a critical role in identifying microsatellite-unstable CRC, such as occur in young patients with synchronous or metachronous tumors or with tumors showing classic histologic features. In these cases, MSI testing and/or MMR immunohistochemistry are advisable, along with gene sequencing and genetic counseling if appropriate. MSI is an excellent functional and prognostically useful marker, whereas MMR immunohistochemistry can guide gene sequencing.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17009390      PMCID: PMC4124399          DOI: 10.3748/wjg.v12.i37.5932

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  66 in total

1.  Multiple genetic diagnoses from single cells using multiplex PCR: reliability and allele dropout.

Authors:  I Findlay; P Matthews; P Quirke
Journal:  Prenat Diagn       Date:  1998-12       Impact factor: 3.050

Review 2.  Lessons from hereditary colorectal cancer.

Authors:  K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

3.  Increasing the denaturation temperature during the first cycles of amplification reduces allele dropout from single cells for preimplantation genetic diagnosis.

Authors:  P F Ray; A H Handyside
Journal:  Mol Hum Reprod       Date:  1996-03       Impact factor: 4.025

4.  p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma.

Authors:  H Elsaleh; B Powell; P Soontrapornchai; D Joseph; F Goria; N Spry; B Iacopetta
Journal:  Oncology       Date:  2000       Impact factor: 2.935

5.  Molecular evolution and intratumor heterogeneity by topographic compartments in muscle-invasive transitional cell carcinoma of the urinary bladder.

Authors:  S J Diaz-Cano; A Blanes; J Rubio; A Matilla; H J Wolfe
Journal:  Lab Invest       Date:  2000-03       Impact factor: 5.662

Review 6.  Genetic susceptibility to non-polyposis colorectal cancer.

Authors:  H T Lynch; A de la Chapelle
Journal:  J Med Genet       Date:  1999-11       Impact factor: 6.318

7.  HMSH6 alterations in patients with microsatellite instability-low colorectal cancer.

Authors:  Y R Parc; K C Halling; L Wang; E R Christensen; J M Cunningham; A J French; L J Burgart; T L Price-Troska; P C Roche; S N Thibodeau
Journal:  Cancer Res       Date:  2000-04-15       Impact factor: 12.701

Review 8.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Authors:  C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

9.  Microsatellite instability in cancer of the proximal colon.

Authors:  S N Thibodeau; G Bren; D Schaid
Journal:  Science       Date:  1993-05-07       Impact factor: 47.728

10.  Hypermutability and mismatch repair deficiency in RER+ tumor cells.

Authors:  R Parsons; G M Li; M J Longley; W H Fang; N Papadopoulos; J Jen; A de la Chapelle; K W Kinzler; B Vogelstein; P Modrich
Journal:  Cell       Date:  1993-12-17       Impact factor: 41.582

View more
  4 in total

Review 1.  Pathologic research update of colorectal neuroendocrine tumors.

Authors:  Shu-Juan Ni; Wei-Qi Sheng; Xiang Du
Journal:  World J Gastroenterol       Date:  2010-04-14       Impact factor: 5.742

Review 2.  Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design.

Authors:  Salvador J Diaz-Cano
Journal:  Int J Mol Sci       Date:  2012-02-13       Impact factor: 6.208

Review 3.  Pathological bases for a robust application of cancer molecular classification.

Authors:  Salvador J Diaz-Cano
Journal:  Int J Mol Sci       Date:  2015-04-17       Impact factor: 5.923

Review 4.  Clinical implications of intratumor heterogeneity: challenges and opportunities.

Authors:  Santiago Ramón Y Cajal; Marta Sesé; Claudia Capdevila; Trond Aasen; Leticia De Mattos-Arruda; Salvador J Diaz-Cano; Javier Hernández-Losa; Josep Castellví
Journal:  J Mol Med (Berl)       Date:  2020-01-22       Impact factor: 4.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.